Lymphoma 'vaccine' given Orphan Drug Designation


On the basis of some encouraging Phase III clinical trial results published last year, the US Food and Drug Administration has granted Orphan Drug Designation to BiovaxID, the so-called 'personalized lymphoma vaccine' from Biovest.

The designation is a boon for Biovest, granting them market exclusivity for seven years following approval, reduced filing fees, tax credits, and possible grant funding for R & D.

Clinical trials by Biovest of BiovaxID have focused primarily on subjects with follicular lymphoma, but the company believes their targeted, customized therapy could be effective against other B-cell cancers, including some lymphomas, leukemias, and even multiple myeloma.

By Ross Bonander

LymphomaInfo Social